Literature DB >> 34189651

Prostate cancer patients' self-reported participation in research: an examination of racial/ethnic disparities.

Nynikka R Palmer1,2, Hala T Borno3,4, Steven E Gregorich5,6, Jennifer Livaudais-Toman5, Celia P Kaplan3,5,6.   

Abstract

PURPOSE: We examined prostate cancer patients' participation in research and associated factors by race/ethnicity in a multiethnic sample.
METHODS: Men with a new diagnosis of prostate cancer were identified through the California Cancer Registry. Patients completed a cross-sectional telephone interview in English, Spanish, Cantonese or Mandarin. Multivariable logistic regression models, stratified by race/ethnicity, estimated the associations of patient demographic and health characteristics with participation in (1) any research, (2) behavioral research, and (3) biological/clinical research.
RESULTS: We included 855 prostate cancer patients: African American (19%), Asian American (15%), Latino (24%), and White (42%). In the overall model of participation in any research, African American men (Odds Ratio (OR) = 2.54, 95% CI 1.63-3.94), and those with two or more comorbidities (OR = 2.20, 95% CI 1.27-3.80) were more likely to report participation. Men 65 years old and older (OR = 0.65, 95% CI 0.47-0.91), those who were married or living with a partner (OR = 0.67, 95% CI 0.45-0.98), and those who completed the interview in Spanish (OR = 0.36, 95% CI 0.15-0.85) were less likely to report participating in any research. Stratified analyses identified racial/ethnic-specific sociodemographic characteristics associated with lower research participation, including Spanish or Chinese language, older age, and lower education.
CONCLUSION: African American prostate cancer patients reported higher research participation than all other groups. However, recruitment efforts are still needed to overcome barriers to participation for Spanish and Chinese speakers, and barriers among older adults and those with lower education levels.
© 2021. The Author(s).

Entities:  

Keywords:  Healthcare disparities; Men; Minority groups; Prostatic neoplasm; Research subjects

Mesh:

Year:  2021        PMID: 34189651      PMCID: PMC8416807          DOI: 10.1007/s10552-021-01463-9

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.532


Introduction

In the United States, prostate cancer (PCa) remains the second leading cause of cancer-related deaths among men [1, 2]. Racial/ethnic disparities in health outcomes, quality of life, and access to treatment among men with PCa are observed on the population level [3]. Emerging literature describes the complex and multifaceted drivers of these observed disparities and the interaction between access to care, quality of care, and genetic and environmental factors [4]. Additionally, health services research has delineated differential access to care that may add to the disparities in outcomes [5]. Differences in culture, attitudes, behaviors, and preferences have also been observed to contribute to variation in PCa outcomes [6]. Lastly, it is well established that the underrepresentation of racial/ethnic minorities in clinical research, compared to White participants, may exacerbate these disparities [7, 8]. To understand racial/ethnic disparities among men with PCa, it is essential to examine all aspects of the cancer care continuum from prevention, screening/early detection, diagnosis, treatment, to survivorship. Participation in all forms of research (e.g., behavioral, biological, clinical trials) is vital to mitigate disparities across this care continuum. Accruing underrepresented racial/ethnic minorities in all aspects of cancer research better ensures that novel therapies and interventions are effective, treatment options are communicated in a culturally and linguistically appropriate manner, and behavioral interventions are acceptable and relevant for all men affected by the disease [9]. A vast literature exists characterizing the problem of racial/ethnic disparities in therapeutic clinical trials research as well as the attitudes and beliefs associated with participation in investigational drug or novel treatment regimens [10, 11]. However, there is limited research on participation rates of racial/ethnic minorities compared to White participants in other types of research such as behavioral/prevention studies. By extension, to date, the factors associated with racial/ethnic minority participation in different types of clinical and behavioral research are not well understood. This study adds to an important area of PCa disparities literature by investigating participation in different types of research among a multiethnic sample. Specifically, in this study, we examined (1) racial/ethnic differences in reported participation in behavioral and biological research and (2) characterized the types of research previously participated in. Given the need for representative study populations in all aspects of research in order to achieve equity in health outcomes [12], this study aims to understand if disparities in minority clinical research participation persist when examined by study type.

Methods

Men diagnosed with PCa in 2008 were recruited from the Greater San Francisco Bay Area and Los Angeles County to participate in a cross-sectional telephone interview between November 2011 and November 2012. All participants were identified from the California Cancer Registry case-listings, a statewide population-based surveillance system.

Eligibility criteria

Participants’ eligibility criteria included (a) self-identification as Black/African American, Latino, Asian American or non-Latino White, (b) diagnosed with stage I and II, localized PCa in 2008, (c) between 18 and 75 years old, (d) speaks Cantonese or Mandarin, Spanish, or English, (e) patients’ physician did not object to their participation, and (f) no physical, cognitive or mental disability. All minority men (African American, Latino, and Asian American) and a random sample of the White men with PCa who met the study criteria were recruited to participate in this study. Letters were mailed to the physicians listed in the California Cancer Registry to identify potential participants who should not be contacted. One month after the physician letters were mailed, eligible participants (those whose physician did not object to their participation) received an introductory recruitment letter in English, Spanish, or Chinese with opt-out options. Our team followed a strict protocol of up to six telephone calls to reach eligible participants. Study participants provided verbal consent by telephone prior to participation. Bilingual interviewers conducted 30-min telephone interviews in the participant’s preferred language. Further details outlining study methods have been described previously [13, 14]. All study activities were approved by the University of California, San Francisco Institutional Review Board (#10-00858) and the California State Committee for the Protection of Human Subjects (#2018-164).

Data measures

Descriptive variables

The study collected the following demographic information: age (categorized as 40–54 years; 55–64 years, ≥ 65 years); self-reported race/ethnicity (Black/African American, Asian American, Latino or non-Latino White); marital status (married or living with a partner vs. other); educational level (high school or less, some college, college degree or beyond); California region (Northern California vs. Southern California); language of interview (English, Spanish, Cantonese or Mandarin); and health insurance coverage (any private vs. public, government or no insurance). If participants reported more than one racial/ethnic group, they were asked to identify which race/ethnicity they most identified with, and we used that response for their self-reported race/ethnicity. For anyone who did not answer the race/ethnicity question, we used the race/ethnicity recorded in the cancer registry. Health literacy was assessed using a validated scale including three questions assessing (a) "How often do you have someone like a family member, friend, hospital worker or caregiver, help you read hospital material;” (b) “How often are you uncomfortable filling out medical forms by yourself?;” and (c) “How often do you have problems learning about your medical condition because of difficulty understanding the written information?” Response categories ranged from 1 = always to 5 = never [15]. A composite health literacy score was created averaging the responses of the three questions. Based on this score, a dichotomous variable for health literacy was created (low health literacy = score < 3.5; medium to high health literacy = score ≥ 3.5).

Health-related indicators

Health status was assessed using one question, how would you rate your health, which was dichotomized into excellent/very good versus good/fair/poor [16]. Participants were asked if they were ever told by a doctor that they had heart disease, high blood pressure, lung disease, diabetes, ulcer or stomach disease, kidney disease, liver disease, other cancer, depression, arthritis, and other health conditions [17]. Responses were categorized into 0, 1, and 2 or more reported comorbidities. The Gleason score (a grading system for PCa tumors) derived from the California Cancer Registry, was dichotomized as 1–6 versus 7–10. PCa treatment modality was self-reported and included active surveillance/watchful waiting, surgery, brachytherapy, external radiation, hormone therapy, chemotherapy, and any other treatment. Treatment was further dichotomized as having received treatment with or without chemotherapy or hormone therapy, as first line of treatment which would indicate greater disease severity.

Outcomes

The survey assessed whether participants reported experience in a health research study, before or after the PCa diagnosis. Four questions specifically inquired about prior research participation in (a) surveys, interviews, or focus groups; (b) collection of blood or tissue samples; (c) clinical trials (e.g., new medicine, medical treatment or procedures; and (d) behavioral change interventions (e.g., diet or exercise). We created four categories of research participation: any, behavioral, biological/clinical, and none. Any research participation was created by a global indicator of participation in any of the research reported above. We combined surveys, interviews, focus groups, and behavioral interventions into behavioral research. And biological/clinical research included the collection of blood or tissue samples and clinical trials.

Statistical analysis

Descriptive statistics were used to summarize study participants’ demographic and health-related characteristics, and to examine differences in demographic characteristics by the three outcomes: participation in any research, behavioral research, or biological/clinical research. Multivariable logistic regression models were fit, reporting odds ratios and 95% confidence intervals (95% CI), in which each model adjusted for age, marital status, education, California region, language of interview, insurance, health literacy, health status, comorbidities, Gleason score, and treatment with or without chemotherapy. Overall adjusted models pooled data across all four racial/ethnic groups and contrasted each minority group with White participants. We also stratified models by race/ethnicity to identify specific factors associated with outcomes within each racial/ethnic group. All statistical analysis were conducted using STATA/SE Version 14.0. The p-value for statistical significance was set to < 0.05.

Results

Study participant characteristics, stratified by participation in research, are listed in Table 1. The analytic sample (n = 855) consisted of 19.2% African American (n = 164), 14.7% Asian American (n = 126), 24.1% Latino (n = 206), and 42% non-Latino White (White; n = 359) men with a history of PCa who completed the survey (45% response rate, 855/1,890). As reported in prior research [13, 14], racial/ethnic differences were noted across all demographic and health-related characteristics. We found statistically significant differences within participation in any, behavioral, and biological/clinical research by various sociodemographic and clinical characteristics. For any research, participants who were African American, less than 64 years old, single/divorced/widowed, had some college education, completed the survey in English, had higher health literacy, or two or more comorbidities reported higher participation. For behavioral research, we found similar significant differences, with the addition of participants who had excellent/very good health status reporting higher participation. Similar significant differences were also noted for biological/clinical research participation, with a slight difference in college graduate or beyond (versus some college education) reported the highest level of participation. We found no significant differences across region, health insurance, Gleason score, or treatment received.
Table 1

Study participant characteristics by participation in research (n = 855)

TotalAny researchp-valueBehavioralp-valueBiological/clinicalp-value
N (%)N (%) YesN (%) YesN (%) Yes
Race< 0.001< 0.001< 0.001
 African American164 (19.2)78 (47.6)60 (36.6)57 (34.8)
 Asian American126 (14.7)21 (16.7)14 (11.1)15 (11.9)
 Latino206 (24.1)35 (17.0)27 (13.1)16 (7.7)
 White359 (42.0)94 (26.2)77 (21.5)58 (16.1)
Age< 0.0010.0250.008
 40–64 years403 (47.6)131 (32.5)98 (24.3)84 (20.8)
 ≥ 65 years444 (52.4)97 (21.9)80 (18.0)62 (14.0)
 Marital status0.001< 0.0010.002
 Single/divorced/widowed204 (24.2)73 (35.8)62 (30.4)50 (24.5)
 Married/living with partner638 (75.8)153 (24.0)114 (17.9)95 (14.9)
Education0.0060.0060.018
 High school or less214 (25.7)40 (18.7)29 (13.6)24 (11.2)
 Some college193 (23.1)59 (30.6)49 (25.4)35 (18.1)
 College graduate or beyond427 (51.2)126 (29.5)97 (22.7)86 (20.1)
Region.769.799.383
 Northern California502 (58.7)132 (26.3)106 (21.1)81 (16.1)
 Southern California353 (41.3)96 (27.2)72 (20.4)65 (18.4)
Language of interview< 0.001< 0.001< 0.001
 English710 (83.0)216 (30.4)171 (24.1)142 (20.0)
 Spanish109 (12.8)10 (9.2)7 (6.4)2 (1.8)
 Cantonese/Mandarin36 (4.2)2 (5.6)02 (5.6)
Health Insurance.252.201.554
 Private663 (79.9)184 (27.8)145 (21.9)116 (17.5)
 Public/government/none167 (20.1)39 (23.4)29 (17.4)26 (15.6)
Health literacy< 0.0010.0010.001
 Low (< 3.5)161 (19.2)25 (15.5)19 (11.8)13 (8.1)
 Medium to high (≥ 3.5)676 (80.8)202 (29.9)158 (23.4)132 (19.5)
Health status0.0910.0270.433
 Good/fair/poor423 (49.5)102 (24.1)75 (17.7)68 (16.1)
 Excellent/very good431 (50.5)126 (29.2)103 (23.9)78 (18.1)
Number of comorbidities0.0210.0140.016
 0119 (14.0)20 (16.8)13 (10.9)13 (10.9)
 1196 (23.0)51 (26.0)42 (21.4)26 (13.3)
 2 or more537 (63.0)157 (29.2)123 (22.9)107 (19.9)
Gleason score0.6770.6800.922
 1–6369 (43.5)101 (27.4)79 (21.4)63 (17.1)
 7–10479 (56.5)125 (26.1)97 (20.3)83 (17.3)
Prostate cancer treatment with hormone therapy or chemotherapy0.3910.5910.927
 Yes130 (15.4)39 (30.0)25 (19.2)22 (16.9)
 No713 (84.6)188 (26.4)152 (21.3)123 (17.3)

Number of missing responses: n = 8 (age); n = 13 (marital status); n = 21 (education); n = 0 (region, language of interview); n = 25 (insurance); n = 18 (health literacy); n = 1 (health status); n = 3 (comorbidities); n = 7 (Gleason score); n = 12 (hormone therapy)

Study participant characteristics by participation in research (n = 855) Number of missing responses: n = 8 (age); n = 13 (marital status); n = 21 (education); n = 0 (region, language of interview); n = 25 (insurance); n = 18 (health literacy); n = 1 (health status); n = 3 (comorbidities); n = 7 (Gleason score); n = 12 (hormone therapy)

Multivariable analysis

In the overall model (Table 2) for participation in any research, African American men (OR = 2.54, 95% CI 1.63–3.94) and those with two or more comorbidities (OR = 2.20, 95% CI 1.27–3.80) were more likely to report participation. Men 65 years old and older (OR = 0.65, 95% CI 0.47–0.91), those who were married or living with a partner (OR = 0.67, 95% CI 0.45–0.98), and those who completed the interview in Spanish (OR = 0.36, 95% CI 0.15–0.85) were less likely to report participating in any research.
Table 2

Adjusted ORs for overall logistic regression models of prior participation in research

Any ResearchN = 792Behavioral ResearchN = 792Biological ResearchN = 792
OR(95% CI)OR(95% CI)OR(95% CI)
Race/ethnicity
 African American2.54*(1.63–3.94)2.12*(1.33–3.36)2.98*(1.83–4.84)
 Asian American0.82(0.46–1.46)0.75(0.39–1.43)0.90(0.46–1.75)
 Latino1.14(0.65–1.98)1.12(0.61–2.03)1.07(0.55–2.08)
 White (ref)
Age
 < 65 years (ref)
 ≥ 65 years0.65*(0.47–0.91)0.81(0.56–1.17)0.74(0.49–1.10)
Marital status
 Single/divorced/widowed (ref)
 Married/living with partner0.67*(0.45–0.98)0.55*(0.36–0.84)0.63*(0.41–0.99)
Education
 College graduate or beyond (ref)
 Some college0.79(0.52–1.19)0.91(0.59–1.42)0.62(0.38–1.01)
 High school or less0.73(0.45–1.19)0.73(0.42–1.27)0.67(0.38–1.17)
Region
 Northern California (ref)
 Southern California1.05(0.75–1.46)0.90(0.63–1.30)1.20(0.82–1.76)
Language of interview
 English (ref)
 Spanish0.36*(0.15–0.85)0.34*(0.12–0.92)0.16*(0.03–0.72)
 Cantonese/Mandarin0.34(0.08–1.54)0.56(0.12–2.63)
Insurance
 Private (ref)
 Public/government/none1.17(0.74–1.85)1.03(0.59–1.78)1.23(0.71–2.14)
Health literacy
 Low (< 3.5)0.71(0.41–1.22)0.77(0.41–1.44)0.59(0.31–1.14)
 Medium to high (≥ 3.5) (ref)
Comorbidities
 0 (ref)
 11.80(0.97–3.31)2.24*(1.12–4.45)1.26(0.60–2.64)
 2 or more2.20*(1.27–3.80)2.54*(1.35–4.77)2.11*(1.11–4.04)
Health status
 Poor/fair/good1.25(0.87–1.79)1.46(0.98–2.17)1.11(0.73–1.68)
 Very good/excellent (ref)1.001.001.00
Gleason score
 1–60.83(0.59–1.18)0.93(0.64–1.36)0.91(0.61–1.37)
 7–10 (ref)1.001.001.00
Treatment with hormone therapy or chemotherapy
 Yes1.17(0.73–1.89)0.76(0.44–1.30)0.90(0.51–1.58)
 No (ref)1.001.001.00

Note The total N is the number of participants who had non-missing responses on every covariate included in the model and therefore were included in the analysis

*p < 0.05

Adjusted ORs for overall logistic regression models of prior participation in research Note The total N is the number of participants who had non-missing responses on every covariate included in the model and therefore were included in the analysis *p < 0.05 With respect to behavioral research, African American men (OR = 2.12, 95% CI 1.33–3.36), those with one comorbidity (OR = 2.24, 95% CI 1.12–4.45), or two or more comorbidities (OR = 2.54, 95% CI 1.35–4.77) were more likely to report participation. Men who were married or living with a partner (OR = 0.55, 95% CI 0.36–0.84) and those who completed the interview in Spanish (OR = 0.34, 95% CI 0.12–0.92) were less likely to report participation in behavioral research. Similarly, African American men (OR = 2.98, 95% CI 1.83–4.84) and those with two or more comorbidities (OR = 2.11, 95% CI 1.11–4.04) were more likely to report participation in biological/clinical research. Men who were married or living with a partner (OR = 0.63, 95% CI 0.41–0.99) or completed the interview in Spanish (OR = 0.16, 95% CI 0.03–0.72) were less likely to report participation in biological/clinical research.

Race/ethnicity stratified multivariable analyses

Participation in any research

Among African American men, those 65 years and older were less likely to report participation in any research (OR = 0.31, 95% CI 0.14–0.70); and those from the Southern California region were significantly more likely to report participation (OR = 2.43, 95% CI 1.16–5.08; Table 3). Among Asian American men, those who completed the interview in Mandarin or Cantonese were less likely to report participation in any research (OR = 0.21, 95% CI 0.05–0.89). Among Latino men, those who completed the interview in Spanish (OR = 0.27, 95% CI 0.11–0.68) were less likely to report participation in any research. However, those who had public, government, or no insurance (OR = 3.61, 95% CI 1.20–10.89) were more likely to report participation. Among White men, those who were from the Southern California region (OR = 0.50, 95% CI 0.29–0.86) were less likely to report participation in any research. White men reporting excellent or very good health status (OR = 2.03, 95% CI 1.13–3.63) or having two or more comorbidities (OR = 2.66, 95% CI 1.16–6.09) were more likely to report participation.
Table 3

Multivariable logistic regression models estimating the effects of patient factors on patient-reported responses to participation in any research, stratified by race/ethnicity

African AmericanN = 148Asian AmericanN = 114LatinoN = 187WhiteN = 343
OR95% CIOR95% CIOR95% CIOR95% CI
Age (ref: < 65 yrs)
 ≥ 65 years0.31*(0.14–0.70)0.67(0.21–2.12)0.56(0.23–1.40)1.01(0.61–1.68)
Marital status (ref: single/divorced/widowed)
 Married/living with partner0.46(0.20–1.06)0.62(0.16–2.36)1.56(0.54–4.53)0.54(0.29–1.00)
Education (ref: college graduate or beyond)
 Some college0.89(0.39–2.03)0.46(0.16–1.36)1.27(0.66–2.42)
High school or less0.60(0.22–1.67)0.26(0.03–2.64)0.34(0.12–1.00)1.16(0.53–2.57)
Language of interview (ref: English)
 Spanish0.27*(0.11–0.68)
 Cantonese/Mandarin0.21*(0.05–0.89)
Region (ref: Northern CA)
 Southern California2.43*(1.16–5.08)0.87(0.28–2.70)2.02(0.88–4.66)0.50*(0.29–0.86)
Insurance (ref: private)
 Public/government/none1.09(0.43–2.74)1.58(0.46–5.46)3.61*(1.20–10.86)0.49(0.20–1.17)
Health literacy (ref: medium to high)
 Low0.81(0.27–2.42)1.49(0.36–6.15)0.69(0.24–1.94)0.51(0.16–1.62)
Health status (ref: Good/fair/poor)
 Excellent/very good0.60(0.27–1.34)0.92(0.29–2.97)1.51(0.59–3.91)2.03*(1.13–3.63)
Comorbidities (ref: 0)
 11.48(0.39–5.59)1.73(0.31–9.60)1.51(0.43–5.37)1.84(0.74–4.59)
 2 or more2.43(0.74–7.99)1.19(0.29–4.89)1.29(0.39–4.27)2.66*(1.16–6.09)
Gleason score (ref: 1–6)
 7–101.07(0.50–2.28)0.61(0.21–1.81)1.05(0.42–2.63)0.63(0.37–1.05)
Treatment with chemotherapy/hormone therapy (ref: no)
 Yes0.80(0.35–1.86)1.36(0.16–11.18)1.88(0.62–5.73)1.19(0.54–2.59)

All models adjusted for all covariates included in the table (except White and African American stratified models were not adjusted for language of interview)

*p < 0.05

Multivariable logistic regression models estimating the effects of patient factors on patient-reported responses to participation in any research, stratified by race/ethnicity All models adjusted for all covariates included in the table (except White and African American stratified models were not adjusted for language of interview) *p < 0.05

Participation in behavioral research

Among African American men, participants having a high school education or less (OR = 0.31, 95% CI 0.11–0.90; Table 4) were less likely to report participation in behavioral research. No factors were associated with participation in behavioral research among Asian American men. Among Latino men, those who completed the survey in Spanish were less likely to report participation in behavioral research (OR = 0.26, 95% CI 0.10–0.70). However, Latino men who reported having public, government, or no insurance (OR = 4.17, 95% CI 1.14–15.21) or reported one comorbidity (OR = 8.12, 95% CI 1.04–63.49) were more likely to report participating in behavioral research. And among White men, those who were married or living together (OR = 0.37, 95% CI 0.19–0.70) or were from the Southern California region (OR = 0.51, 95% CI 0.28–0.94) were less likely to report participation in behavioral research. Alternatively, White men who reported excellent or very good health status (OR = 2.36, 95% CI 1.25–4.45) or had two or more comorbidities (OR = 3.28, 95% CI 1.29–8.35) were significantly more likely to report participation in behavioral research.
Table 4

Multivariable logistic regression models estimating the effects of patient factors on patient-reported responses to participation in behavioral research, stratified by race/ethnicity

African AmericanN = 148Asian AmericanN = 114LatinoN = 187WhiteN = 343
OR95% CIOR95% CIOR95% CIOR95% CI
Age (ref: < 65 yrs)
 ≥ 65 years0.47(0.21–1.10)1.62(0.37–7.14)0.75(0.27–2.10)1.15(0.66–2.01)
Marital status (ref: single/divorced/widow)
 Married/living together0.43(0.19–1.00)0.55(0.09–3.34)1.64(0.49–5.49)0.37*(0.19–0.70)
Education (ref: college graduate or beyond)
 Some college0.95(0.41–2.19)0.54(0.17–1.72)1.31(0.66–2.60)
 High school or less0.31*(0.11–0.90)0.25(0.02–3.71)0.32(0.10–1.04)1.65(0.71–3.82)
Language of interview (ref: English)
 Spanish0.26*(0.10–0.70)
 Cantonese/Mandarin
Region (ref: Northern CA)
 Southern California2.01(0.95–4.26)0.41(0.08–2.14)1.49(0.58–3.82)0.51*(0.28–0.94)
Insurance (ref: private)
 Public/government/none1.35(0.51–3.56)1.81(0.44–7.47)4.17*(1.14–15.21)0.40(0.15–1.06)
Health literacy (ref: medium to high)
 Low0.81(0.24–2.74)0.44(0.05–3.64)0.92(0.29–2.93)0.67(0.21–2.15)
Health status (ref: Good/fair/poor)
 Excellent/very good0.70(0.30–1.64)0.53(0.13–2.24)2.81(0.94–8.41)2.36*(1.25–4.45)
Comorbidities (ref: 0)
 11.01(0.25–4.19)1.18(0.14–9.72)8.12*(1.04–63.49)2.14(0.77–5.94)
 2 or more2.01(0.56–7.20)0.52(0.11–2.49)4.93(0.68–35.81)3.28*(1.29–8.35)
Gleason score (ref: 1–6)
 7–101.51(0.68–3.32)0.55(0.15–2.09)1.39(0.50–3.90)0.64(0.37–1.13)
Treatment with chemotherapy/hormone therapy (ref: no)
 Yes0.66(0.26–1.66)0.61(0.04–8.56)1.10(0.31–3.88)0.60(0.23–1.57)

All models adjusted for all covariates included in the table (except White and African American stratified models were not adjusted for language of interview)

*p < 0.05

Multivariable logistic regression models estimating the effects of patient factors on patient-reported responses to participation in behavioral research, stratified by race/ethnicity All models adjusted for all covariates included in the table (except White and African American stratified models were not adjusted for language of interview) *p < 0.05

Participation in biological/clinical research

Few variables were associated with participation in biological research for all racial/ethnic groups (Table 5). Among African American men, older participants (OR = 0.38, 95% CI 0.17–0.84) were less likely to participate in biological research; and those from Southern California region (OR = 2.21, 95% CI 1.06–4.59) were more likely to participate. No factors were associated with biological research participation among Asian American men. Among Latino men, those with some college education (OR = 0.20, 95% CI 0.04–0.94) or those who completed the interview in Spanish (OR = 0.07, 95% CI 0.01–0.64) were significantly less likely to report participation in biological research. Latino men from Southern California (OR = 4.34, 95% CI 1.15–16.34) were more likely to report participation in biological research compared to Northern California participants. In contrast, White men from Southern California were significantly less likely to report participation in biological research (OR = 0.51, 95% CI 0.27–0.98).
Table 5

Multivariable logistic regression models estimating the effects of patient factors on patient-reported responses to participation in biological research, stratified by race/ethnicity

African AmericanN = 148Asian AmericanN = 114LatinoN = 187WhiteN = 343
OR95% CIOR95% CIOR95% CIOR95% CI
Age (ref: < 65 yrs)
 ≥ 65 years0.38*(0.17–0.84)0.95(0.28–3.24)0.51(0.13–2.04)1.14(0.62–2.11)
Marital status (ref: single/divorced/widow)
 Married/living together0.49(0.22–1.09)0.26(0.06–1.09)3.57(0.56–22.80)0.54(0.27–1.09)
Education (ref: college graduate or beyond)
 Some college0.85(0.36–2.03)0.20*(0.04–0.94)0.88(0.42–1.87)
 High school or less0.99(0.35–2.81)0.43(0.04–5.02)0.44(0.09–2.11)0.47(0.16–1.37)
Language of interview (ref: English)
 Spanish0.07*(0.01–0.64)
 Cantonese/Mandarin0.22(0.04–1.16)
Region (ref: Northern CA)
 Southern California2.21*(1.06–4.59)1.51(0.42–5.40)4.34(1.15–16.34)0.51*(0.27–0.98)
Insurance (ref: private)
 Public/government/none1.11(0.42–2.96)1.73(0.43–7.00)4.34(0.51–37.20)0.66(0.24–1.81)
Health literacy (ref: medium to high)
 Low0.65(0.21–2.07)2.37(0.56–10.04)0.19(0.02–1.49)0.42(0.10–1.78)
Health status (ref: Good/fair/poor)
 Excellent/very good0.82(0.38–1.80)0.84(0.23–3.08)1.07(0.30–3.75)1.44(0.73–2.83)
Comorbidities (ref: 0)
 10.82(0.20–3.29)1.45(0.19–11.04)0.79(0.13–4.68)1.67(0.51–5.43)
 2 or more1.54(0.48–4.99)1.89(0.34–10.50)1.59(0.29–8.63)2.48(0.83–7.38)
Gleason score (ref: 1–6)
 7–100.87(0.39–1.90)0.64(0.18–2.30)1.09(0.34–3.54)0.89(0.49–1.64)
Treatment with chemotherapy/hormone therapy (ref: no)
 Yes0.54(0.22–1.33)1.72(0.18–16.80)1.69(0.41–6.95)0.79(0.31–1.97)

All models adjusted for all covariates included in the table (except White and African American stratified models were not adjusted for language of interview)

*p < 0.05

Multivariable logistic regression models estimating the effects of patient factors on patient-reported responses to participation in biological research, stratified by race/ethnicity All models adjusted for all covariates included in the table (except White and African American stratified models were not adjusted for language of interview) *p < 0.05

Conclusion

Using a population-based survey of a multi-ethnic cohort of men with a history of PCa, this study aimed to assess racial/ethnic disparities in self-reported research participation. Attention to research participation is warranted due to the paucity of research among racial/ethnic minority groups and the limited investigation of participation in different types of research. Our findings indicate that African American men were more likely to report prior research participation (both behavioral and biological) than White men; and Asian American and Latino men did not significantly differ from White men. However, enhanced recruitment efforts, such as tailoring materials, methods and messages [18], may be needed to address identified barriers (e.g., language, lower education, and older age), particularly among men with PCa who have never participated in research. Providing linguistically appropriate materials, and language and culturally concordant interviewers or research coordinators can help increase minority research participation [19, 20]. Factors associated with increased research participation included two or more comorbidities, excellent or very good health status, public/government/no insurance, and living in the Southern California region. While one of the most common reasons patients are excluded from clinical trials is multiple comorbid conditions [21-23], our study found that men with one or more comorbidities were more likely to report research participation, particularly among Latino and White men. This may be due in part to our inclusion of behavioral research, as comorbidities are often not of concern for exclusion. Additionally, patients with comorbidities may have more opportunities to participate in research, as studies are typically geared towards disease and these patients likely engage more frequently with health care systems conducting research. Patients with comorbidities may also be more inclined to participate to improve their health, as previous studies have noted reasons for research participation include the belief that patients in clinical trials receive better health care [15], along with the possibility of benefiting personally and the potential to help others [24, 25]. We also found participants with excellent and very good health status reported greater research participation; however, this was only found among White men reporting participation in any and behavioral research. Although insurance coverage has been reported as a barrier to clinical trial participation in cancer [26], Latino men in our study with public/government/no insurance were more likely to report participation in any and behavioral research. A research study that oversamples Latino men, based in California and linked to a state-funded treatment program for uninsured men with PCa since 2006 [27, 28], may have contributed to our finding. Additionally, living in the Southern California region was associated with greater participation in biological research among Latino men, and biological and behavioral research among African American men. This finding may be due to a larger population of African American and Latino men in this region, compared to Northern California. Factors associated with lower research participation among individual racial/ethnic groups included older age, being married or living together, having less than a college education, Spanish or Chines language, and living in the Southern California region (for White men). Older age (65 years or older) was associated with less research participation, which is consistent with previous research, despite a persistent awareness of this disparity [29, 30]. Not only is older age the greatest risk factor for cancer, but individuals 65 years and older are a rapidly increasing age group. This lack of participation may be due to upper age cut-offs in research, the likelihood of increasing comorbidities and frailty with age that might hinder participation, and a lack of intentional recruitment efforts [31]. Being married or living with a partner was significantly associated with lower reported participation in all types of research (any, behavioral, and biological) in the overall model. In race-stratified analyses, being married or living together was only significant among White participants for behavioral research. This is an unusual finding as previous studies have noted family members can influence decisions to participate in research and marital status has been a significant predictor of general willingness to participate for male respondents [32, 33]. However, previous studies have reported inconsistent findings [34]. Stryker and colleagues did not find significant associations between research participation and marital status, although their sample was only 24% male [35]. A study in Brazil found 61% of female respondents were significantly influenced by a spouse in the decision to participate in a trial, while 73% of male respondents were not influenced by a spouse [36]. Similarly, a survey in Taiwan found respondents who were married or lived with a significant other were less likely to participate in medical research [37]. These discrepant findings could be due to population and gender differences; however, more research is needed to further clarify this finding. Lower education (high school or less) was associated with African American participants being less likely to participate in behavioral research, which is similar to previous studies, although results have been mixed [38, 39]. And some college education was associated with Latino participants being less likely to participate in biological/clinical research. This could be due to a lack of knowledge of research (e.g., clinical trials) and lack of explanation of procedures involved in participation. Studies have noted increasing patients’ understanding about research procedures, including clinical trials, and risks and benefits may enhance research participation and improve participants’ informed decisions [39, 40]. Similar to other studies [38, 41], participants who preferred to complete the interview in Spanish or Chinese were less likely to report participation in research. Studies have noted language and cultural differences can be a barrier to research participation [42, 43]. As a result, researchers should consider minimizing language barriers using bilingual materials (including audio-aided consenting information in preferred language), hiring bilingual and culturally concordant research staff, and utilizing translation services, which helps to establish trust and overcome language or dialect barriers [44, 45]. Additionally, the Southern California region was associated with less reported participation in any and all types of research among White participants. This may be due to National Institutes of Health mandates for recruitment efforts among historically under-represented minority populations [46], and that the Southern California region has a larger minority population than Northern California. Several limitations to our study are worth noting. First, we relied on self-reports of prior research participation which are subject to recall bias and do not capture recruitment efforts. Second, we did not assess preferred language for healthcare interactions specifically, and we did not evaluate limited English proficiency, or use of interpreters during clinical visits; instead we used language preferred for interview as a proxy. Third, we were unable to disaggregate data on either Asian American or Latino participants due to small subgroup sample sizes. This prevented more nuanced analyses that might capture the diversity within racial/ethnic subgroups (e.g., geographic, cultural, and linguistic backgrounds). As a result, we could not determine whether the disparities we found were due to cultural differences in how patients consider research participation. Additionally, while our response rate of 45% is reasonable and fairly similar to other telephone-based surveys [47], it is a bit lower compared to some studies using state cancer registries [48, 49]. This may also reflect lower response rates among men versus women as noted in previous studies [50, 51]. Lastly, our study recruited men from the California Cancer Registry in 2008 with stage I or II PCa (e.g., localized disease), and by the time we completed interviews in 2012, 15% no longer had localized disease, which may not be representative of PCa patients across the United States. Limitations notwithstanding, this study significantly adds to the literature by examining racial/ethnic disparities in self-reported research participation among a multiethnic and multilingual, understudied population. Building upon previous research, this study delves deeper into factors associated with research participation within each racial/ethnic group. In conclusion, some minority men with PCa report research participation. However, future studies should address factors contributing to lower reports of research participation among minorities—specifically language barriers—and developing targeted efforts to address older minority patients and those with less education.
  48 in total

1.  Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation.

Authors:  Joseph M Unger; Dawn L Hershman; Mark E Fleury; Riha Vaidya
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Research challenges and lessons learned from conducting community-based research with the Hmong community.

Authors:  Jennifer Kue; Sheryl Thorburn; Karen Levy Keon
Journal:  Health Promot Pract       Date:  2014-12-01

Review 4.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

Review 5.  Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials.

Authors:  Carol A Townsley; Rita Selby; Lillian L Siu
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

6.  Recruitment and retention challenges and successes.

Authors:  Trina M Aguirre; Ann E Koehler; Ashish Joshi; Susan L Wilhelm
Journal:  Ethn Health       Date:  2016-10-21       Impact factor: 2.772

7.  The Symbolic Value and Limitations of Racial Concordance in Minority Research Engagement.

Authors:  Craig S Fryer; Susan R Passmore; Raymond C Maietta; Jeff Petruzzelli; Erica Casper; Natasha A Brown; James Butler; Mary A Garza; Stephen B Thomas; Sandra C Quinn
Journal:  Qual Health Res       Date:  2015-03-13

8.  Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members.

Authors:  Marvella E Ford; Laura A Siminoff; Elisabeth Pickelsimer; Arch G Mainous; Daniel W Smith; Vanessa A Diaz; Lea H Soderstrom; Melanie S Jefferson; Barbara C Tilley
Journal:  Health Soc Work       Date:  2013-02

9.  Predicting prostate cancer treatment choices: The role of numeracy, time discounting, and risk attitudes.

Authors:  Belén López-Pérez; Andrew Barnes; Dominick L Frosch; Yaniv Hanoch
Journal:  J Health Psychol       Date:  2015-11-26

10.  Racial/Ethnic Disparities in Genomic Sequencing.

Authors:  Daniel E Spratt; Tiffany Chan; Levi Waldron; Corey Speers; Felix Y Feng; Olorunseun O Ogunwobi; Joseph R Osborne
Journal:  JAMA Oncol       Date:  2016-08-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.